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ABSTRACT
Systemic lupus erythematosus (SLE) is a chronic
multisystem autoimmune disorder in which
20 % of patients are diagnosed in childhood.
Childhood-onset SLE is associated with higher
morbidity and mortality than adult-onset SLE.
The aims of disease management with early
immunosuppression are to decrease disease
activity and improve quality of life. A
multidisciplinary approach is necessary due to
the complexity of lupus in pediatric patients. It
is important to provide patients with high
quality of care and to instill ownership of their
disease process from a young age to prepare
them to manage this life-long illness. This
article reviews current management of SLE in
children.
Keywords: Autoimmune; Management;
Medication; Pediatric; Rheumatology; Systemic
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic
multisystem autoimmune connective tissue
disorder that manifests with a broad spectrum of
clinical phenotypes. Approximately 20 % of SLE
patients are diagnosed in childhood [1]. The
average age of onset of pediatric SLE is between
12and14 years and rarelybefore theageof5 years
[2]. Childhood-onset SLE is associated with
greater lifetime morbidity and mortality than
adult-onset SLE [3]. Physicians have commonly
relied on the American College of Rheumatology
(ACR) Criteria for the classification of SLE. These
criteria were preliminarily developed in 1971,
revised in 1982, andupdated in 1997 [4]. A person
canbe classified ashaving SLE if at least four of the
11 criteria are present. In order to address
limitations of the ACR criteria, the Systemic
Lupus International Collaborating Clinics
(SLICC) developed the SLICC Classification
Criteria in 2012, which exhibited a higher
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sensitivity and lower specificity than the ACR
criteria [5]. The SLICC criteria include 11 clinical
and six immunologic items. Classification criteria
require four items with at least one clinical and
one immunologic item, or biopsy-proven
nephritis compatible with lupus in the presence
of an ANA or anti-dsDNA [5]. The SLICC criteria
has been validated in children, showing better
sensitivity and fewer misclassifications than the
ACR criteria [6]. Of note, these are no diagnostic
criteria, and somepatientsneed treatmentdespite
not fitting classification criteria.
Children with SLE are at a significantly
higher risk of disease damage than adults with
SLE [7]. A multidisciplinary therapeutic
approach is necessary in order to treat
pediatric SLE (pSLE). In this review, we aim to
provide and review the recommendations for
the management of children with SLE. This
article is based on previously conducted studies
and does not involve any new studies of human
or animal subjects performed by any of the
authors.
Quality Indicators for pSLE
In 2013, an international consensus was
reached for the first set of quality indicators
for pSLE patients. The consensus resulted in 26
quality indicators for pSLE (Table 1). Although
there are similarities to quality indicators
proposed for adult SLE, distinct pediatric
concerns were incorporated, including high
dose glucocorticoid therapy at diagnosis,
antibody profile testing, ophthalmology
screening, treatment of lupus nephritis, and
monitoring for medication safety [3].
Treatment of pSLE
Medical management of pSLE differs between
providers, but will usually have the same
principal approach. Most patients will require
glucocorticoids and often immunosuppressive
drugs, with the aim of reducing disease activity
while also preventing long-term toxicities from
medications. There are ongoing studies to
develop treatment guidelines.
Glucocorticoids
Glucocorticoids are the mainstay of
pharmacological treatment in patients with
pSLE with or without major organ
involvement. Glucocorticoids are given mainly
as oral prednisone, prednisolone, or
intravenous high-dose methylprednisolone.
Daily doses of glucocorticoids can vary
among providers, and can range from 0.5 to
2 mg/kg/day. The initial dose is decided by the
extent of disease severity and organ
involvement. Taper of glucocorticoid doses is
usually based on improvement in disease
activity, including improving physical exam
and symptoms, and response to treatment,
with respect to improvement in laboratory
parameters. In general, laboratory parameters
that help decide whether a decrease in
glucocorticoids is warranted include
improvements in complement levels (usually
to normal), improvement in anti-dsDNA levels,
improvement of cytopenias, or other specific
laboratory abnormalities such as a decrease in
creatinine kinase and decrease in urine
protein-to-creatinine ratios.
Intravenous methylprednisolone (IVMP) at a
dose of 30 mg/kg to a max of 1 g (for 1–5
consecutive days) is usually initiated at
diagnosis. IVMP helps decrease the IFN
signature of disease activity in lupus. Increased
expression of IFN-regulated genes, termed the
IFN signature, correlates with autoantibodies in
lupus [8]. These signatures are not decreased
with oral glucocorticoids. The dosing of
glucocorticoids is highly variable among
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Table 1 Quality indicators for patients with childhood-onset SLE by domain Hollander et al. [3] with permission from
Wiley
Laboratory testing around the time of diagnosis
1. IF a patient has suspected childhood-onset SLE, THEN the following laboratory studies should be obtained (see
Table 3)a
2. IF a patient has conﬁrmed childhood-onset SLE, THEN the following laboratory studies should be obtained (see
Table 3)
General prevention
3. IF a patient has childhood-onset SLE, THEN vaccination against inﬂuenza and encapsulated organisms, including
pneumococcus, meningococcus, and Haemophilus inﬂuence, should be prescribed, unless there are contraindications
4. IF a patient has childhood-onset SLE, THEN education about sun avoidance should be documented at least once in
the medical record (e.g., wearing protective clothing, applying sunscreens whenever outdoors, and avoiding
sunbathing)b
5. IF an adolescent has childhood-onset SLE, THEN a transition plan should be carefully designed to facilitate transfer of
care to the appropriate adult health care providers
LN and hypertension management
6. IF a patient has a ﬂare after having achieved remission of kidney disease, THEN diligent follow-up of renal disease is
needed
7. IF a patient has newly diagnosed LN, THEN renal biopsy, urine sediment analysis, proteinuria, and kidney function
should all be assessedb
8. IF a patient is diagnosed with proliferative childhood-onset SLE nephritis (WHO or ISN/RPS class III or IV), THEN
therapy with corticosteroids combined with another immunosuppressive agent should be provided and documented
within 1 month of this diagnosis, unless contraindicatedb
9. IF a childhood-onset SLE patient without known LN has developed daily proteinuria of[500 mg or clinically relevant
worsening of GFR/urinary sediment, THEN a kidney biopsy should be performed
10. IF a patient has known LN, THEN a clinical assessment for childhood-onset SLE should occur at least every
3 months, regardless of disease activity
11. IF a childhood-onset SLE patient has LN plus evidence of ongoing proteinuria[500 mg/day, THEN an
angiotensin-converting enzyme inhibitor or angiotensin receptor blockers should be prescribed, unless there are
contraindicationsc
12. IF a patient has LN and/or hypertension, THEN disease comanagement with a nephrologist should be considered
Medication management
13. IF a patient is prescribed a new medication for childhood-onset SLE (e.g., NSAIDs, DMARDs, or glucocorticoids),
THEN a discussion with the patient about the risks versus beneﬁts of the chosen therapy should be documentedb
14. IF a patient has childhood-onset SLE, THEN antimalarial therapy should be prescribed, unless there are
contraindications
15. IF a childhood-onset SLE patient is receiving a dose of steroids not acceptable for long-term use, then an attempt
should be made to taper steroidsb
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pediatric rheumatologists. There have been
initiatives to attempt to standardize steroid
treatment, particularly for lupus nephritis
(LN). In 2012, the Childhood Arthritis
Rheumatology Research Alliance published
consensus treatment plans for induction
Table 1 continued
16. IF a patient with childhood-onset SLE is unable to decrease the dose of steroids acceptable for long-term use, THEN
the addition of a steroid-sparing agent or an increased dose of an existing steroid-sparing agent should be consideredb
17. IF a childhood-onset SLE patient is treated with medications, THEN laboratory surveillance for medication safely
should done at regular intervals (details provided in Table 4)b
Bone health
18. IF a patient has received chronic systemic steroids, THEN the patient should have bone mineral density testing
documented in the medical record
19. IF baseline bone mineral density testing is outside of the normal limits (Z scores of -2 or less), THEN bone mineral
density should be remeasured after 1 year
20. IF a patient is receiving any steroid therapy, THEN calcium and vitamin D supplementation should be recommended
after 3 months
Ophthalmologic surveillance
21. IF a childhood-onset SLE patient is treated with corticosteroids, THEN eye screening should be done at least annually
22. IF a childhood-onset SLE patient is treated with antimalarial therapy. THEN eye screening should be done at least
annually
Education on cardiovascular risk factors
23. IF a patient has childhood-onset SLE, THEN education about cardiovascular risk factors should occur in regular
intervals with the parent and the patient age C13 years (see Table 5)
24. IF a patient has childhood-onset SLE, THEN lifestyle modiﬁcations (smoking cessation, weight control, exercise) are
likely to be beneﬁcial for patient outcomes and should be encouragedb
Pregnancy
25. IF a patient with childhood-onset SLE is pregnant, THEN anti-SSA, anti-SSB, and antiphospholipid antibodies
should be documented in the medical recordb
Neuropsychiatric manifestations
26. IF a patient with childhood-onset SLE has major neuropsychiatric manifestations (optic neuritis, acute confused
state/coma, cranial or peripheral neuropathy, psychosis, and transverse myelitis/myelopathy), THEN
immunosuppressive therapy should be consideredb
SLE systemic lupus erythematosus, LN lupus nephritis, WHO World Health Organization, ISN/RPS International Society
of Nephrology/Renal Pathology and Society, GFR glomerular ﬁltration rate, NSAIDs nonsteroidal anti-inﬂammatory drugs,
DMARDs diseases-modifying antirheumatic drugs
a Suspected SLE is often deﬁned as fulﬁlling three of 11 criteria for lupus diagnosis as deﬁned by the American College of
Rheumatology
b Adult quality indicators (endorsed by the American College of Rheumatology or the European League Against
Rheumatism) that achieved consensus for childhood-onset SLE
c Ongoing proteinuria is deﬁned as persistence of proteinuria for C3 months
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therapy of LN [9]. These guidelines can be found
in Fig. 1. Cyclophosphamide and
mycophenolate mofetil, both of which are a
part of these guidelines, will be discussed later
in this review. Early side effects of steroids
include endocrine manifestations such as
hyperglycemia and weight gain, which are
reversible with tapering but may lead to
diabetes mellitus, obesity, hypertension,
hyperlipidemia, and atherosclerosis [10]. While
on steroids, it is important to track height and
weight, which should improve as steroid
therapy is tapered or discontinued. Physical
body changes, including Cushingoid features
and striae, should be discussed often with
patients. A healthy diet low in salt should be
reiterated to prevent fluid retention and
hypertension. Long-term glucocorticoids can
also cause osteoporosis, so along with
adequate calcium and vitamin D intake, a
bone mineral density scan is performed
annually [11]. Glucocorticoids can also cause
cataracts and increased risk of glaucoma, which
may lead to visual field loss and even blindness
[12].
Hydroxychloroquine
Hydroxychloroquine is an antimalarial agent
given to almost all patients with adult or
pediatric SLE. Hydroxychloroquine inhibits
Toll-like receptor pathways and minimizes
flare, treats skin disease, and decreases the rate
of autoantibody production [13, 14,]. The usual
prescribed dose of hydroxychloroquine is 4–6/
mg/kg/day. Additionally, hydroxychloroquine
has an important role in cardiovascular
protection, such as anti-platelet,
anti-thrombotic, lipid-regulating,
Fig. 1 Consensus treatment plan for proliferative juvenile systemic lupus erythematosus—associated lupus nephritis
(Source: [9]) with permission from Wiley
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anti-hypertensive, hypoglycemic properties,
which are important to consider in SLE
patients [15]. This adjunctive treatment is
usually continued for a prolonged period of
time. Patients require ophthalmological
screening for hydroxychloroquine induced
retinopathy, which can present insidiously
with subtle color vision changes and
paracentral scotoma, making early detection
difficult [16]. Early screening is important to
possibly arrest its progression, thereby averting
or lessening visual loss [17].
Mycophenolate Mofetil
Mycophenolate mofetil has been a heavily
studied drug, particularly in the treatment of
lupus nephritis. Trials in adults have
demonstrated that mycophenolate mofetil has
equivalent or better results than
cyclophosphamide [18]. Studies have also
shown that mycophenolate mofetil has lower
rates of adverse effects, particularly infections,
for the 6-month induction phase and long-term
maintenance in comparison to
cyclophosphamide [19]. The usual dosage of
mycophenolate mofetil is 600 mg/m2/dose
twice daily with a maximum dosage of
1500 mg taken two times per day [9]. MMF
can also be used as a steroid sparing agent in
dermatological manifestations of SLE. Side
effects of mycophenolate mofetil include mild
gastrointestinal symptoms, cytopenias, and
teratogenicity. It is important to note that
African Americans may require higher doses of
mycophenolate mofetil due to increased
clearance of the drug [20]. Urine pregnancy
tests are done while on MMF and patients
should be appropriately counseled on fetal
toxicity and teratogenicity. With evidence of
increased risk of miscarriage and birth defects
associated with MMF use, the FDA instituted a
REMS program that contains both a medication
guide and elements to assure safe use [21].
Cyclophosphamide
Cyclophosphamide is primarily used for the
management of severe SLE, including lupus
nephritis, life-threatening organ involvement,
and neuropsychiatric manifestations.
Cyclophosphamide has been a well-established
treatment for lupus nephritis for many years
[22]. In lupus nephritis induction therapy,
intravenous cyclophosphamide is given every
4 weeks for 6 months [8]. The European
protocol for treating lupus nephritis, which
consists of low-dose IV cyclophosphamide
(500 mg) every 2 weeks for six doses, has also
proven to be an effective initial treatment
regimen [23].
It is important to counsel female patients
about fertility issues. SLE patients exposed to
cyclophosphamide have a much higher risk of
developing infertility and premature ovarian
failure than do the counterparts who are treated
with other less-toxic treatments [24].
Cyclophosphamide can permanently alter the
ovarian reserve in a manner that is dose-,
duration-, and age-dependent, and patients
should be counseled to use effective
contraception until the end of treatment, and
a minimum of one ovulation cycle after the end
of treatment is recommended before
considering conception [25]. Patients can
consider GnRH agonists to prevent cycles. It
was initially thought that cyclophosphamide
led to increased infections. These infections,
when thought to be related to
cyclophosphamide therapy, have been in the
setting of cyclophosphamide-induced
reductions in total WBC count [26]. However,
current literature supports that the current
recommended regimens significantly lower
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adverse effects like infections whilst not
affecting efficacy [27]. It is important to
counsel patients of an increased risk of bladder
cancer with the use of cyclophosphamide,
which has been found to be dose-dependent.
Azathioprine
Azathioprine is used to help treat lupus
nephritis, as well as dermatologic and
hematologic manifestations of pSLE [28].
Thiopurine methyltransferase (TPMT), an
enzyme that metabolizes azathioprine, can be
tested in order to titrate dosing to prevent
azathioprine toxicity. Azathioprine is a category
D drug, so there is positive evidence of risk
during pregnancy. It should be continued
during pregnancy if the benefits outweigh the
risks. There is also an increased risk of cancers,
particularly skin cancers and lymphomas, with
use of azathioprine. Blood test monitoring is
important in detecting azathioprine-related
toxicity. Neutropenia, lymphopenia, and
deranged liver function may be relevant and
indicate myelotoxicity, susceptibility to
infection, and hepatotoxicity, respectively [29].
Rituximab
An anti-CD20 monoclonal antibody, rituximab,
targets B-cells and their ability for antibody
production. Studies have shown that that
rituximab is particularly effective in treating
SLE-associated cytopenias [30]. In patients with
severe SLE organ involvement, benefit has been
shown inusing rituximab and cyclophosphamide
together [31]. Prior to initiating therapy with
rituximab, CBCwith flowcytometry, quantitative
immunoglobulins, and vaccine titers are usually
obtained. Patients should be carefully monitored
due to increased risk of infections. Serum
immunoglobulin levels and flow cytometry are
important labs to monitor after B cell depletion
and can help decide whether to continue
anti-CD20 monoclonal antibody therapy [32].
Patients may require IVIG replacement therapy
for hypogammaglobulinemia.
Vitamin D and Calcium
Patients should be counseled and monitored for
proper intake of Vitamin D and calcium. Long
term use of glucocorticoids and renal disease
make adequate Vitamin D and calcium intake
even more important.
Potential Future Therapies
Belimumab was approved in the USA and
Europe in 2011 for the treatment of adults
with autoantibody-positive SLE [33]. Current
trials are studying its use in pSLE. Belimumab is
a human IgG1 monoclonal antibody that binds
to soluble BLyS and inhibits its biological
activity. Increased BLyS levels are associated
with greater disease activity in SLE. BLyS may
increase the ability of autoreactive B cells to
escape regulatory mechanisms and differentiate
into autoantibody-secreting plasma cells [34].
Belimumab has been shown to be effective in
autoantibody-positive adult SLE patients with
moderately active disease whose clinical
manifestations are predominantly
mucocutaneous and/or musculoskeletal and
emerging data confirms that pSLE patients
with similar characteristics also respond
favorably to belimumab, in particular,
suggesting a potential role for belimumab as a
steroid-sparing agent [35].
Another pathway developing for lupus
treatment is the mTOR blockade with the use
of rapamycin. This is currently being studied to
treat refractory lupus in children. Rapamycin
blocks T cell activation in patients with SLE
with remarkable therapeutic efficacy since the
activation of mTORC1 preceded disease flares
and responded to therapeutic intervention with
rapamycin [36].
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Other future therapies target IFN-regulated
genes. Chronic activation of the innate immune
system in SLE, including upregulated
IFN-regulated genes (IFN signature), has led to
the development of biologic agents targeting
this cytokine in SLE [37].
Barriers to Treatment
A multidisciplinary approach is needed to
provide best practices in the care of pSLE
patients. Social and psychological problems,
mood changes and depression, disease
complications, or drug-related issues are
common in teenagers with chronic diseases
such as lupus, and require special attention by
psychologists and social workers [38].
Appropriately educating pSLE patients and
involving them in their care plan is essential.
Pediatric patients with rheumatic diseases may
not be sufficiently engaged in their medical care
or unwilling to engage, and therefore lack
understanding of the purposes of their
medications [39]. Encouraging patients to
develop self-care skills, especially as they
transition to adult care, is important.
Non-adherence is associated with poorer
health perceptions, self-esteem, mental health,
family cohesion, and social functioning [40].
Psychosocial and educational interventions
targeted at improving confidence, self-efficacy,
disease-related knowledge, social support, and
resolving insecurities regarding patients’
capacity for self-management may alleviate
psychosocial distress and improve adherence
and health outcomes of adolescents and young
adults with SLE [41].
Transition of care is an important time in a
pSLE patient’s life. The successful transition from
pediatric to adult care for patients with chronic
conditions is predicated on the ability of the
individual to achieve self-efficacy and disease
self-management skills as well as the ability of
the medical system to provide patient-centered
care [42]. A recent study regarding transition of
SLE patients showed that transfer of care from
pediatric to adult providers was characterized by
moderately high disease activity, prolonged time
between the last pediatric and first adult provider
appointments, and frequent gaps in care [42].
Major challenges with transition of pSLE
patients are loss of insurance and attachment
to pediatric providers [43]. This supports the
need for a structured transition process that
helps prepare patients for the expectations of
adult care. Continued follow-up studies are
needed to solidify strategies that will be proven
to be successful over a long period of time.
CONCLUSIONS
Providing care for pSLE patients is a unique
experience. It is important to consider each
patient’s particular SLE manifestations to
provide proper care. Advances in treatment
options provided better disease responses and
effective control of disease activity. Chronic
burden of illness, psychosocial factors, and
medication adherence all make this journey
challenging. Increasing knowledge of the
pathogenesis of SLE and autoimmune
processes will help target new and innovative
therapies.
It is also imperative to prepare patients for
differences in autonomy of care as they
eventually transition to adult care. Adult
providers should be sensitive to patients who
are used to a pediatric clinical experience. In
turn, pediatric practitioners need to provide
patients with ownership of their disease,
education about pSLE and medications, and an
understanding that a diagnosis of pSLE is a
lifelong challenge.
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